WO2001098467A3 - Regulation de la serine protease humaine de type prostasine - Google Patents

Regulation de la serine protease humaine de type prostasine Download PDF

Info

Publication number
WO2001098467A3
WO2001098467A3 PCT/EP2001/007117 EP0107117W WO0198467A3 WO 2001098467 A3 WO2001098467 A3 WO 2001098467A3 EP 0107117 W EP0107117 W EP 0107117W WO 0198467 A3 WO0198467 A3 WO 0198467A3
Authority
WO
WIPO (PCT)
Prior art keywords
human prostasin
regulation
serine protease
reagents
prostasin
Prior art date
Application number
PCT/EP2001/007117
Other languages
English (en)
Other versions
WO2001098467A2 (fr
Inventor
Yonghong Xiao
Vladimir Morozov
Original Assignee
Bayer Ag
Yonghong Xiao
Vladimir Morozov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Yonghong Xiao, Vladimir Morozov filed Critical Bayer Ag
Priority to AU2001266089A priority Critical patent/AU2001266089A1/en
Publication of WO2001098467A2 publication Critical patent/WO2001098467A2/fr
Publication of WO2001098467A3 publication Critical patent/WO2001098467A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Réactifs régulant l'activité enzymatique humaine de type prostasine et réactifs se liant aux produits géniques enzymatiques humains de type prostasine qui peuvent être utilisés pour réguler l'activité enzymatique humaine de type prostasine. Cette régulation est particulièrement utile pour traiter les métastases de cellules malignes, l'angiogenèse tumorale, les inflammations, la bronchopneumopathie chronique obstructive, l'athérosclérose, les maladies neurodégénératives et les infections pathogènes.
PCT/EP2001/007117 2000-06-23 2001-06-22 Regulation de la serine protease humaine de type prostasine WO2001098467A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001266089A AU2001266089A1 (en) 2000-06-23 2001-06-22 Regulation of human prostasin-like serine protease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21358800P 2000-06-23 2000-06-23
US60/213,588 2000-06-23
US27690901P 2001-03-20 2001-03-20
US60/276,909 2001-03-20

Publications (2)

Publication Number Publication Date
WO2001098467A2 WO2001098467A2 (fr) 2001-12-27
WO2001098467A3 true WO2001098467A3 (fr) 2002-04-04

Family

ID=26908219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007117 WO2001098467A2 (fr) 2000-06-23 2001-06-22 Regulation de la serine protease humaine de type prostasine

Country Status (2)

Country Link
AU (1) AU2001266089A1 (fr)
WO (1) WO2001098467A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE317399T1 (de) * 2000-06-23 2006-02-15 Regulierung der menschlichen prostasin-änhlichen serine protease
WO2004106536A2 (fr) * 2003-05-28 2004-12-09 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees a la serine protease 8 (prss8)
US7947436B2 (en) 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500344A (en) * 1992-12-03 1996-03-19 The United States Of America As Represented By The Department Of Health And Human Services Serine protease and uses thereof
WO1999046391A2 (fr) * 1998-03-12 1999-09-16 Millennium Biotherapeutics, Inc. Nouvelles molecules d'acides nucleiques et de proteines pdsp et utilisations correspondantes
EP1130094A2 (fr) * 1999-07-08 2001-09-05 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500344A (en) * 1992-12-03 1996-03-19 The United States Of America As Represented By The Department Of Health And Human Services Serine protease and uses thereof
WO1999046391A2 (fr) * 1998-03-12 1999-09-16 Millennium Biotherapeutics, Inc. Nouvelles molecules d'acides nucleiques et de proteines pdsp et utilisations correspondantes
EP1130094A2 (fr) * 1999-07-08 2001-09-05 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_EST EMBL; 14 October 1998 (1998-10-14), NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP), TUMOR GENE INDEX HTTP://WWW.NCBI.NIH.GOV/NCICGAP: "Homo sapiens cDNA clone", XP002183965 *
DATABASE EM_EST EMBL; 21 February 2000 (2000-02-21), NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP), TUMOR GENE INDEX HTTP://WWW.NCBI.NIH.GOV/NCICGAP: "Homo sapiens cDNA clone", XP002183964 *
YU JACK X ET AL: "Molecular Cloning, Tissue-specific Expression, and Cellular Localization of Human Prostasin mRNA.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 22, 1995, pages 13483 - 13489, XP002935257, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2001098467A2 (fr) 2001-12-27
AU2001266089A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2001096538A3 (fr) Regulation de la serine protease transmembranaire humaine
Sorsa et al. A trypsin‐like protease from Bacteroides gingivalis: partial purification and characterization
Kato et al. Production of trypsins by human gastric cancer cells correlates with their malignant phenotype
AU2001259353A1 (en) Novel mutated form of arginine deiminase
WO2002008392A3 (fr) Regulation de la serine protease humaine semblable a matriptase
Zucker et al. Extraction of type‐IV collagenase/gelatinase from plasma membranes of human cancer cells
O'Mahony et al. Angiostatin generation by human pancreatic cancer
Oliveira et al. Simplified procedures for the isolation of HF3, bothropasin, disintegrin-like/cysteine-rich protein and a novel PI metalloproteinase from Bothrops jararaca venom
WO2002053146A3 (fr) Inhibiteurs de la metalloproteinase matricielle
WO2001098467A3 (fr) Regulation de la serine protease humaine de type prostasine
Clemmensen Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin
Frederick Woessner MMPs and TIMPs: an historical perspective
WO2001096378A3 (fr) Regulation de la serine protease humaine de type epithin
WO2002014264A3 (fr) (hydroxyethyl)urees utilisees en tant qu'inhibiteurs de la production de beta-amyloide de la maladie d'alhzeimer
WO2001098340A3 (fr) Regulation d'une enzyme du type protease mastocytaire humaine 6
WO2001098466A3 (fr) Regulation de la serine protease semblable a la prostasine humaine
De et al. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease
WO2002012461A3 (fr) Regulation de la serine protease membranaire humaine
WO2002026957A3 (fr) Regulation de la serine protease humaine
WO2002024886A3 (fr) Regulation de la serine protease humaine
WO2002000702A3 (fr) Regulation de la serine protease specifique de l'epiderme humain
WO2001079466A3 (fr) Regulation de la serine protease semblable a l'epithine humaine
WO2002018565A3 (fr) Regulation de l'enzyme humaine de type proteine phosphatase iic
WO2002006453A3 (fr) Regulation de protease a serine humaine de type desc1
WO2001090160A3 (fr) Regulation de la serine/threonine kinase humaine analogue a p78

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP